Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 276

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort

Gobbini, Elisa, Ezzalfani, Monia, Dieras, Véronique, Bachelot, Thomas, Brain, Etienne, Debled, Marc, Jacot, William, Mouret-Reynier, Marie Ange, Goncalves, Anthony, Dalenc, Florence, Patsouris, Anne, Ferrero, Jean Marc, Levy, Christelle, Lorgis, Veronique, Vanlemmens, Laurence, Lefeuvre-Plesse, Claudia, Mathoulin-Pelissier, Simone, Petit, Thierry, Uwer, Lionel, Jouannaud, Christelle, Leheurteur, Marianne, Lacroix-Triki, Magali, Cleaud, Audrey Lardy, Robain, Mathieu, Courtinard, Coralie, Cailliot, Christian, Perol, David, Delaloge, Suzette · 2018 · European Journal of Cancer

Abstract

AIM Real-life analysis of overall survival (OS) trends among metastatic breast cancer (MBC) patients may help define medical needs and evaluate the impact of public health investments. The present study aimed to evaluate the independent impact of the year of MBC diagnosis on OS in the Epidemio-Strategy-Medical-Economical (ESME)-MBC cohort. METHODS ESME-MBC (NCT03275311) is a French, national, multicentre, observational cohort including 16,702 consecutive newly diagnosed MBC patients (01 January 2008-31 December 2014). Of 16,680 eligible patients, 15,085 had full immunohistochemistry data, allowing classification as hormone receptor-positive and HER2-negative (HR+/HER2-, N = 9907), HER2-positive (HER2+, N = 2861) or triple-negative (HR-/HER2-, N = 2317) subcohorts. Multivariate analyses of OS were conducted among the full ESME cohort and subcohorts. RESULTS Median OS of the whole cohort was 37.22 months (95% confidence interval [CI], 36.3-38.04). Year of diagnosis was an independent predictor of OS (hazard ratio 0.98 [95% CI, 0.97-1.00], P = .01) together with age, subtype, disease-free interval, visceral metastases and number of organs involved. Median OS of HR+/HER2-, HER2+ and HR-/HER2- subcohorts was, respectively, 42.12 (95% CI, 40.90-43.10), 44.91 (95% CI, 42.51-47.90) and 14.52 (95% CI, 13.70-15.24) months. Year of diagnosis was a strong independent predictor of OS in HER2+ subcohort (hazard ratio 0.91 [95% CI, 0.88-0.94], P < .001), but not in HR+/HER2- nor HR-/HER2- subcohorts (hazard ratio 1.00 [95% CI, 0.98-1.01], P = .80 and 1.00 [95% CI, 0.97-1.02], P = .90, respectively). CONCLUSIONS The OS of MBC patients has slightly improved over the past decade. However, this effect is confined to HER2+ cases, highlighting the need of new strategies in the other subtypes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2018.03.015

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 1

  1. Tai, 2004, Survival of patients with metastatic breast cancer: twenty-year data from two SEER registries, BMC Cancer, 4, 60, 10.1186/1471-2407-4-60 · doi:10.1186/1471-2407-4-60

Cited by

See all 276

Metadata

Authors
Gobbini, E., Ezzalfani, M., Dieras, V., Bachelot, T., Brain, E., Debled, M., Jacot, W., Mouret-Reynier, M. A., Goncalves, A., Dalenc, F., Patsouris, A., Ferrero, J. M., Levy, C., Lorgis, V., Vanlemmens, L., Lefeuvre-Plesse, C., Mathoulin-Pelissier, S., Petit, T., Uwer, L., Jouannaud, C., Leheurteur, M., Lacroix-Triki, M., Cleaud, A. L., Robain, M., Courtinard, C., Cailliot, C., Perol, D., & Delaloge, S.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2018-06
Volume
96
Pages
17-24
ISSN
0959-8049 (ISSN-L)
OpenAlex
W2796557635
Cited by
276
References
23
FWCI
9.55
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. https://app.cochat.ai/papers/10.1016/j.ejca.2018.03.015
The paper
Gobbini, E., Ezzalfani, M., Dieras, V., Bachelot, T., Brain, E., Debled, M., Jacot, W., Mouret-Reynier, M. A., Goncalves, A., Dalenc, F., Patsouris, A., Ferrero, J. M., Levy, C., Lorgis, V., Vanlemmens, L., Lefeuvre-Plesse, C., Mathoulin-Pelissier, S., Petit, T., Uwer, L., . . . Delaloge, S. (2018). Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2018.03.015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.